Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

Figitumumab (CP-751,871) for cancer therapy

(2010) Antonio Gualberto   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

(2009) Paul Haluska et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Development of the Monoclonal Antibody Figitumumab, Targeting the Insulin-like Growth Factor-1 Receptor, for the Treatment of Patients with Non–Small-Cell Lung Cancer

(2009) Antonio Gualberto et al.   Clinical Lung Cancer

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

(2009) David R. Gandara et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

(2008) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY